Pimobendan

Drug Profile

Pimobendan

Alternative Names: Acardi; UDCG 115; UDCG 115A; UDCG 115BS

Latest Information Update: 07 Sep 2009

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
  • Class Cardiotonics; Pyridazines; Small molecules
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Heart failure
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 07 Sep 2009 Discontinued for Heart failure in USA (PO)
  • 07 Sep 2009 Discontinued for Heart failure in European Union (PO)
  • 07 Sep 2009 Discontinued for Heart failure in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top